CA
NZ
UK
AU
IND
US
AngioDynamics (NASDAQ:ANGO), a Latham, New York medical technology company focused on vascular disease and cancer treatment, is edging higher in pre-market trading. Shares are at $15.40, up 1.85% from Thursday's close of $15.12, slightly ahead of a healthcare sector fund up about 0.4%.
Artiva Biotherapeutics (NASDAQ:ARTV), a San Diego clinical-stage company developing off-the-shelf natural killer cell therapies for autoimmune diseases, is rebounding in pre-market trading after closing Thursday at $6.79. Shares are at $7.14, up 5.15%, with no new announcement identified for Friday.
BioCardia Inc (NASDAQ:BCDA), a company focused on cellular and cell derived therapeutics for cardiovascular and pulmonary disease, announced it has completed a revised De Novo pre-submission to the FDA's Center for Devices and Radiological Health for its Helix catheter. The device is designed to …
Candel Therapeutics (NASDAQ:CADL), a Needham, Massachusetts clinical-stage company developing off-the-shelf immunotherapies for cancer, is climbing in pre-market trading after closing Thursday at $10.16, down 2.68%. Shares are at $10.70, up 5.32%, and no new clinical or regulatory announcement has been identified for the session.
Ensign Group (NASDAQ:ENSG), the San Juan Capistrano, CaliforniaHolding Companybehind a network of skilled nursing and senior living operators, is edging higher in pre-market trading after a large batch ofAcquisitionannouncements. Shares are at $172.00, up 1.40% from Thursday's close of $169.63.
Johnson & Johnson (NYSE:JNJ) presented late breaking two year data from its Phase 3 ICONIC-TOTAL trial at the European Academy of Dermatology and Venereology Congress, evaluating ICOTYDE, a targeted oral peptide that blocks the IL-23 receptor, in adults and adolescents with plaque psoriasis affecting …
Kailera Therapeutics (NASDAQ:KLRA), a Waltham, Massachusetts clinical-stage biotech building an obesity pipeline around GLP-1-based injectable and oral drugs, is rising in pre-market trading after closing Thursday at $11.03. Shares are changing hands at $11.65, up 5.62%, though no new company announcement has been identified …
NANOBIOTIX (NASDAQ:NBTX), a late stage clinical biotechnology company developing physics based approaches to cancer and other major diseases, announced the appointment of Arnd Christ as chief financial officer and member of its executive board, effective October 1, 2026. Christ succeeds Bart Van Rhijn, who …
Novartis (NYSE:NVS) is edging higher in pre-market trading after announcing the licensing agreement with Abogen. Shares are at $142.17, up 0.79% from Thursday's close of $141.05, a muted reaction for a deal with a headline value of up to $7.8 billion.
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) announced that the European Medicines Agency has validated its Marketing Authorisation Application for rebisufligene etisparvovec, an investigational single dose gene therapy designed to treat MPS IIIA, more commonly known as Sanfilippo syndrome Type A. Validation confirms the application is sufficiently …
Please wait processing your request...